TNF-308 and TNF-238 promoter polymorphism phenotypes and TNFα promoter haplotypes in SLE and serological subsets of disease
| TNFα promoter phenotype | Controls (n = 234) | SLE (n = 147) | Ro (n = 38) | La (n = 19) | U1RNP (n = 55) | Sm (n = 18) | aCL (>low) (n = 15) | DNA (n = 107) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| −308G | 215 (93%) | 135 (92%) [0.3] | 32 (84%) [0.1] | 14 (74%) [0.1] | 52 (95%) | 17 (95%) | 15 (100%) | 100 (93%) | ||||||||
| −308A | 85 (36%) | 65 (44%) | 21 (55%) [2.2] | 16 (84%) [9.4] | 21 (38%) | 7 (39%) | 4 (27%) | 38 (36%) | ||||||||
| −238G | 233 (100%) | 143 (97%) | 37 (97%) | 18 (95%) | 55 (100%) | 18 (100%) | 15 (15%) | 103 (96%) | ||||||||
| −238A | 29 (12%) | 9 (6%) | 3 (8%) | 2 (11%) | 1 (2%) [0.1] | 0 (0%) | 0 (0%) | 9 (8%) |
| TNFα promoter haplotype | Controls (n = 224) | SLE (n = 142) | Ro (n = 36) | La (n = 19) | U1RNP (n = 52) | Sm (n = 17) | aCL (>low) (n = 14) | DNA (n = 103) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Odds ratios in square brackets. | ||||||||||||||||
| TNFα, tumour necrosis factor α; SLE, systemic lupus erythematosus. | ||||||||||||||||
| TNF1 | 175 (79%) | 101 (71%) | 25 (69%) | 11 (58%) | 37 (71%) | 15 (88%) | 10 (71%) | 76 (74%) | ||||||||
| TNF2 | 78 (35%) | 60 (42%) | 19 (53%) [2.1] | 16 (84%) 11 | 19 (37%) | 6 (35%) | 4 (29%) | 34 (33%) | ||||||||
| TNF3 | 72 (32%) | 45 (32%) | 7 (19%) | 2 (11%) | 18 (35%) | 1 (6%) | 5 (36%) | 32 (31%) | ||||||||
| TNF4 | 27 (12%) | 11 (8%) | 4 (11%) | 1 (5%) | 3 (6%) | 2 (12%) | 1 (75) | 9 (9%) | ||||||||
| TNF5 | 27 (12%) | 8 (6%) [0.5] | 2 (6%) | 2 (11%) | 1 (2%) | 0 (0%) | 0 (0%) | 8 (8%) | ||||||||
| TNF6 | 1 (0%) | 1 (1%) | 0 (0%) | 0 (0%) | 1 (2%) | 0 (0%) | 0 (0%) | 0 (0%) | ||||||||